Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Relay Therapeutics logo — Integrating leading-edge computational and experimental scie...

Relay Therapeutics

Integrating leading-edge computational and experimental science to transform human health.

Founded 2016 United States Cambridge, United States 230 employees IPO Total: $2.12B Biotechnology, Health Care +1

General Information

Company Name Relay Therapeutics
Founded Year 2016
Location United States Cambridge, United States
Founders / Decision Makers
Team member
Employees 230
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage IPO
Business Model B2B, B2C, B2B2C
Revenue Model Licensing, Performance Based, Product Sales
Hiring 7 roles posted in the month to 8 Nov 2026
Social

BounceWatch is an independent company data service, not affiliated with Relay Therapeutics. To contact Relay Therapeutics, visit relaytx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Relay Therapeutics compare?

A PDF of Relay Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Relay Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Actively Hiring Nov 03, 2026

Hiring for 8 positions in the last 30 days.

Event Participation Oct 21, 2026

Relay Therapeutics vascular anomalies team participated in PeDRA2026 in Virginia, presenting a poster on zovegalisib.

Relay Therapeutics a competitor of yours? Have our desk watch it

AI Insight

Bounce Watch AI
1 month ago

Relay Therapeutics continues its post-IPO growth trajectory, securing additional Post IPO Equity funding in September 2026, following a substantial $316 million raise in June 2026. Concurrent with these capital inflows, the company is actively recruiting for 5 new positions. This coordinated activity signals a strategic expansion of its team and capabilities, likely to accelerate its precision medicines pipeline and clinical development efforts.

Signal Types
Funding Hiring
Strategic Labels
Capitalization Team Expansion Pipeline Advancement
Next Move: Expansion
·
Impact: 8/10
·
Ideal For: Biotech Investors — Growth Equity

About Relay Therapeutics

Relay Therapeutics, founded in 2016 and headquartered in the United States, is setting the pace in the Biotechnology and Health Care sectors. They proudly stand by their slogan: "Integrating leading-edge computational and experimental science to transform human health."

The company operates as a clinical-stage precision medicines organization, which is revolutionizing the drug discovery process by focusing on protein motion and its link to protein function. Their approach harnesses computational power and advanced experimental techniques in structural biology, biophysics, chemistry, and biology, allowing them to develop unique therapies.

Relay Therapeutics recently attracted attention with a post-IPO equity investment on 01 September 2026, though details on investors were not disclosed. This move highlights their commitment to advancing novel therapies, making them a compelling prospect for investment in the competitive landscape of health innovation.

Business keywords: Precision Medicines, Drug Discovery, Protein Motion, Allosteric Drug Discovery, Structural Biology, Biophysics, Computational Techniques, Experimental Science, Chemistry, Cancer Therapeutics, Breast Cancer, Rare Diseases, Therapeutic Development, Oncology, Clinical-Stage Biotechnology

Services & Products

Motion-Based Drug Design
Dynamo Platform Integration
Therapeutics Development
Precision Medicine

Target Customers

Patients with Genetic Disease Oncology Patients Healthcare Providers Medical Researchers Pharmaceutical Investors

Funding Rounds & Investors (12)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity Undisclosed -
01 Sep 2026
Post-IPO Equity $316.00M -
01 Jun 2026
Post-IPO Equity $150.00K 1
IEQ Capital
01 Sep 2025
Post-IPO Equity $200.00M -
01 Sep 2024
Private Placement VC $30.00M 1
Nextech
Nextech
01 Jan 2024
Post-IPO Equity $300.00M -
01 Sep 2022
Post-IPO Equity $350.00M -
01 Oct 2021
IPO $400.00M -
01 Jul 2020
Series C $400.00M 9
Casdin Capital Foresight Group SoftBank
Casdin Capital, Foresight Group +7
01 Dec 2018
Series B $63.00M 5
Casdin Capital Third Rock Ventures BVF Partners
Casdin Capital, Third Rock Ventures +3
01 Dec 2017

View All 12 Funding Rounds

Relay Therapeutics Alternatives & Competitors

View All Alternatives
Relay Therapeutics vs
Treeline
Treeline United States

Making medicines at the highest level

Series A
172 employees
Biotechnology, Health Care
Compare Relay Therapeutics vs Treeline
Relay Therapeutics vs
Monte Rosa Therapeutics
Monte Rosa Therapeutics United States

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecu...

IPO
230 employees
Biotechnology, Health and Wellness
Relay Therapeutics vs
Moderna
Moderna United States

Our mission is to deliver the greatest possible impact to people through mRNA medicines.

Grant
6245 employees
Biotechnology, Health Care
Also compare with: Relay Therapeutics vs Mosaic TX Mosaic TX View all alternatives

FAQ About Relay Therapeutics

Integrating leading-edge computational and experimental science to transform human health.
Relay Therapeutics was founded in 2016.
Relay Therapeutics is headquartered in Cambridge, United States.
Relay Therapeutics operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Precision Medicines, Drug Discovery, Protein Motion and Allosteric Drug Discovery. Its customers include Patients with Genetic Disease, Oncology Patients and Healthcare Providers.
Relay Therapeutics has a B2B, B2C and B2B2C business model. Its revenue comes from Licensing, Performance Based and Product Sales.
Relay Therapeutics has approximately 230 employees.
Relay Therapeutics has completed 12 funding rounds, raising a total of $2.12B. The latest funding stage is IPO.
Relay Therapeutics offers: Motion-Based Drug Design, Dynamo Platform Integration, Therapeutics Development, Precision Medicine.
Top alternatives and competitors to Relay Therapeutics include Treeline, Monte Rosa Therapeutics, Moderna, Arcus Biosciences, Mosaic TX. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Relay Therapeutics and Treeline are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Relay Therapeutics, https://bouncewatch.com/company/relay-therapeutics, updated 8 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout